PROKIDNEY CORP. (PROK) research

PROKIDNEY CORP.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$1.85
As of

PROKIDNEY CORP. (PROK): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-10.

As of . Source: SEC EDGAR filings for PROK. Method and limitations.

SHARE THIS CARD

Share the PROK intelligence card

A branded snapshot of PROK: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion PROK intelligence card preview
Post to X
LIVE TERMINAL

See PROK live in the terminal

Track PROK's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live PROK terminal, free

Active signals for PROK

FREE, NO ACCOUNT

Every signal on PROK, as it fires

You are seeing 5 of 12 signals recorded on PROK since 2026-05-17.

The five above landed across 2 days. The other 7 were recorded on 3 other days. 8 of the 12 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in PROK (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 74291D104 · 2026Q2$2.2M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 74291D104 · 2026Q2$2.2M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 74291D104 · 2026Q2$557K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, PROK

PROK mentioned in Kresmion daily briefs

PROK against its peers

PROK's operating margin of -18477.8% ranks in the 4th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.

MetricPROKPeer medianPercentilen
Revenue FY893000 USD35.5M USD1714
Operating margin-18477.8%-201.1%412
Net margin-7725.2%-191.5%412
Return on equityn/a-72.2%n/a20

Peers (23): LRMR, PRLD, GALT, BNTC, FENC, BBOT, AGEN, MYGN, RCKT, DMAC, TTRX, CCCC, ARCT, ARTV, OBIO, OCGN, ZURA, EDIT, IRD, CABA, XFOR, ENTA, RLMD. Left out: RZLT (no annual filing), PRTC (period gap). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PROK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more PROK signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PROKand get the insider, 13F, options, and confluence read in one view.

Open the live PROK terminal, free